LYEL · Lyell Immunopharma Inc
United States · RS rating 31 · As of 2026-11-03
| Price | 10.77 USD |
|---|---|
| 1-day change | -1.0% |
| RS rating (overall / 1M / 3M / 12M) | 31 / 93 / 31 / 28 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 22 / 14 / 34 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -210.9% |
| Sales growth Q/Q | -60.0% |
| Distance from 52-week high | +72.1% |
| Market cap (USD) | $550.6M |